UCB stock: ING targets EUR 304.00 for UCB stock

Published on 10/23/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BIMZELX sales reached EUR 1.52 billion in H1 2026. UCB stock costs EUR 265.10 on October 23, 2026, up 2.32 percent versus the Xetra close.

Analyst target and reporting date

ING set a EUR 304.00 target for UCB on October 22, 2026.
BIMZELX sales reached EUR 1.52 billion in the first half of 2026.
UCB stock costs EUR 265.10 at Lang & Schwarz on October 23, 2026 at 4:41 p.m. CEST, 2.32 percent above the Xetra close of October 22, 2026, and 8.43 percent below the 52-week high.
UCB will publish full-year 2026 results on February 25, 2027.

Makroaufnahme eines dreidimensionalen Molekülmodells mit farbigen Kugeln vor unscharfem Laborhintergrund — UCB S.A. (BE0003739530) veranschaulicht durch scharfe Makroaufnahme einer dreidimensionalen Molekülstruktur im Forschungslabor, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) stock is covered by ING, which set a EUR 304.00 target on October 22, 2026, according to MarketScreener. The target lies 14.67 percent above UCB's EUR 265.10 price at 4:41 p.m. CEST on October 23, 2026. In trading, UCB was at EUR 265.10 at Lang & Schwarz on October 23, 2026 at 4:41 p.m. CEST, up 2.32 percent versus the Xetra close of October 22, 2026 at EUR 259.10.

BIMZELX sales lead the portfolio

BIMZELX sales reached EUR 1.52 billion in the first half of 2026, while CIMZIA sales were EUR 954 million in the same period, according to UCB. The figures underline the commercial weight of immunology products in the company's current portfolio. BIMZELX also reached more than 135,000 patients globally in the first half of 2026, according to the same investor information.

What does the price position imply?

The EUR 265.10 Lang & Schwarz price on October 23, 2026 stood 8.43 percent below the 52-week high of EUR 289.50 and 34.26 percent above the 52-week low of EUR 197.45. The market capitalization was EUR 50.5 billion, the price-to-earnings ratio was 22.92, and volume was 218,376 shares as of October 23, 2026. The stock's year-to-date performance was plus 28.45 percent.

Valuation and the next date

ING's EUR 304.00 target leaves 14.67 percent upside from the EUR 265.10 Lang & Schwarz price on October 23, 2026. The target is one of several analyst reference points cited by MarketScreener, which also reported EUR 270.00 from KBC Securities and EUR 220.00 from Jefferies on October 22, 2026. UCB's next specified reporting date is February 25, 2027, when it will publish full-year 2026 results and formal financial guidance for 2027, according to UCB.

Comparison with peers

UCB: up 2.32 percent, price-to-earnings ratio 22.92, market capitalization EUR 50.5 billion as of October 23, 2026.

Amgen (Nasdaq, USD): down 1.06 percent, price-to-earnings ratio 27.50, market capitalization USD 239.2 billion as of October 23, 2026.

Biogen (Nasdaq, USD): down 1.87 percent, price-to-earnings ratio 44.01, market capitalization USD 36.8 billion as of October 23, 2026.

UCB stock remains below its yearly high

UCB combines a 2.32 percent daily gain with a price that remains below its yearly high. The EUR 304.00 ING target is the clearest near-term valuation marker, while the February reporting date offers the next scheduled company checkpoint. UCB was trading at EUR 265.10 at Lang & Schwarz on October 23, 2026 at 4:41 p.m. CEST, 2.32 percent above the Xetra close of October 22, 2026 at EUR 259.10. The further course of trading is shown by the continuously updated real-time quote of UCB stock.